A comparison of the efficacy of a bispyridinium oxime - 1,4-bis-(2-hydroxyiminomethylpyridinium) butane dibromide and currently used oximes to reactivate sarin, tabun or cyclosarin-inhibited acetylcholinesterase by in vitro methods

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG38__%2F04%3A00001074" target="_blank" >RIV/60162694:G38__/04:00001074 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

A comparison of the efficacy of a bispyridinium oxime - 1,4-bis-(2-hydroxyiminomethylpyridinium) butane dibromide and currently used oximes to reactivate sarin, tabun or cyclosarin-inhibited acetylcholinesterase by in vitro methods

Popis výsledku v původním jazyce

The efficacy of a bispyridinium oxime 1,4-bis(2-hydroxyiminomethylpyridinium) butane dibromide, called K033, and currently used oximes (pralidoxime, obidoxime, the oxime HI-6) to reactivate acetylcholinesterase inhibited by various nerve agent (sarin, tabun cyclosarin) was tested by in vitro methods. The new oxime K033 was found to be more efficacious reactivator of sarin or cyclosarin-inhibited acetylcholinesterase than pralidoxime and obidoxime but it did not reach the efficacy of the oxime HI-6 in the case of the inhibition of acetylcholinesterase by sarin or cyclosarin. On the other hand, the oxime K033 is more efficacious than the oxime HI-6 to reactivate tabun-inhibited acetylcholinesterase. Thus, the oxime K033 seems to be relatively efficaciousbroad spectrum acetylcholinesterase reactivator and, therefore, it could be useful if no information about the type of nerve agent used is available.

Název v anglickém jazyce

A comparison of the efficacy of a bispyridinium oxime - 1,4-bis-(2-hydroxyiminomethylpyridinium) butane dibromide and currently used oximes to reactivate sarin, tabun or cyclosarin-inhibited acetylcholinesterase by in vitro methods

Popis výsledku anglicky

The efficacy of a bispyridinium oxime 1,4-bis(2-hydroxyiminomethylpyridinium) butane dibromide, called K033, and currently used oximes (pralidoxime, obidoxime, the oxime HI-6) to reactivate acetylcholinesterase inhibited by various nerve agent (sarin, tabun cyclosarin) was tested by in vitro methods. The new oxime K033 was found to be more efficacious reactivator of sarin or cyclosarin-inhibited acetylcholinesterase than pralidoxime and obidoxime but it did not reach the efficacy of the oxime HI-6 in the case of the inhibition of acetylcholinesterase by sarin or cyclosarin. On the other hand, the oxime K033 is more efficacious than the oxime HI-6 to reactivate tabun-inhibited acetylcholinesterase. Thus, the oxime K033 seems to be relatively efficaciousbroad spectrum acetylcholinesterase reactivator and, therefore, it could be useful if no information about the type of nerve agent used is available.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

<a href="/cs/project/OBVLAJEP20032" target="_blank" >OBVLAJEP20032: C-AGENS - Zdravotnická problematika ochrany živé síly proti aktuálním typům vojensky použitelných chemických látek</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2004

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmazie

ISSN

0031-7144

e-ISSN

—

Svazek periodika

59

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

4

Strana od-do

795-798

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—